N0289

Nafamostat mesylate

≥98% (HPLC), powder, serine protease inhibitor

• Synonyme(s) : 4-[(Aminoiminomethyl)amino]benzoic acid 6-(aminoiminomethyl)-2-naphthalenyl ester dimethanesulfonate, FUT-175
• Formule empirique (notation de Hill) : C₁₉H₁₇N₅O₂ · 2CH₄O₃S
• CAS Number: 82956-11-4
• Poids moléculaire : 539.58
• Numéro MDL: MFCD00941430
• Code UNSPSC : 51111800
• ID de substance PubChem : 329818423
• Nomenclature NACRES : NA.77

Propriétés

• Product Name: Nafamostat mesylate, ≥98% (HPLC)
• Niveau de qualité: 100
• Essai: ≥98% (HPLC)
• Forme: powder
• Couleur: white to beige
• Solubilité: DMSO: 10 mg/mL, clear; H₂O: >10 mg/mL
• Température de stockage: room temp
• Chaîne SMILES: CS(O)(=O)=O.CS(O)(=O)=O.NC(=N)Nc1ccc(cc1)C(=O)Oc2ccc3cc(ccc3c2)C(N)=N
• InChI: 1S/C19H17N5O2.2CH4O3S/c20-17(21)14-2-1-13-10-16(8-5-12(13)9-14)26-18(25)11-3-6-15(7-4-11)24-19(22)23;2*1-5(2,3)4/h1-10H,(H3,20,21)(H4,22,23,24);2*1H3,(H,2,3,4)
• Clé InChI: SRXKIZXIRHMPFW-UHFFFAOYSA-N

Description

Application

Nafamostat mesylate has been used:

• as a serine protease inhibitor to study its effects on proteolytic degradation of therapeutic proteins recombinantly expressed in Chinese hamster ovary (CHO)-K1-derived cells
• to stop complement activation to validate the assay for murine C3 fragments
• as a serine protease inhibitor to study its effects on house dust mite extract evoked Ca²⁺ entry

Actions biochimiques/physiologiques

Nafamostat mesylate is a broad spectrum serine protease inhibitor, kallikrein inhibitor, and inhibits blood coagulation.

Nafamostat mesylate is a broad spectrum serine protease inhibitor, kallikrein inhibitor, and inhibits blood coagulation. It is also a possible complement inhibitor.

Nafamostat mesylate is used in the treatment of disseminated intravascular coagulation (DIC), pancreatitis, and systemic inflammatory response syndrome. It can block the proliferation, adhesion, and invasion of cancer cells and repress tumor progression in animal models. Nafamostat mesylate is involved in the development of immune activity. In combination with favipiravir, nafamostat mesylate may block virus entry and replication, and inhibit the pathogenic host response. This combination treatment might be effective for critically ill Covid-19 patients.

Informations sur la sécurité

• Pictogrammes: GHS08
• Mention d'avertissement: Warning
• Mentions de danger: H361fd
• Conseils de prudence: P201 - P202 - P280 - P308 + P313 - P405 - P501
• Classification des risques: Repr. 2
• Code de la classe de stockage: 11 - Combustible Solids
• Classe de danger pour l'eau (WGK): WGK 3
• Point d'éclair (°F): Not applicable
• Point d'éclair (°C): Not applicable
• Équipement de protection individuelle: Eyeshields, Gloves, type N95 (US)